HIV Program

About Prosetta Biosciences

Prosetta Biosciences is a private, preclinical-stage biotech pioneering a novel drug discovery paradigm centered on modulating the assembly of cellular multi-protein complexes. Its platform, inspired by viral assembly mechanisms, has generated a pipeline with lead programs in neurodegenerative diseases like ALS/FTD and Alzheimer's, as well as in antiviral, antibacterial, and oncology indications. The company is led by founder and CEO/CTO Dr. Vishwanath R. Lingappa and is supported by a scientific advisory board including notable figures like Dr. Dale Bredesen. While demonstrating promising preclinical data, Prosetta remains pre-revenue and faces the significant risks inherent in advancing a first-in-class technology through clinical development.

About Vichem Chemie Research

Vichem Chemie Research is a Budapest-based, private contract research organization (CRO) and drug discovery company with a 30+ year history. Its core business model combines fee-for-service chemistry and biology work with the development of its own proprietary chemical libraries and internal therapeutic programs, primarily focused on kinase inhibitors. The company leverages strategic alliances and has received grant funding from Hungarian and European sources, indicating a hybrid revenue model of services and grants while advancing its pipeline.

Therapeutic Areas